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Abstract
Circulating cell-free DNA (cfDNA) has been described as a prognostic marker for several diseases. Its prognostic value
for short-term outcome in stroke patients treated with intravenous thrombolysis remains unexplored. cfDNA was
measured on admission in 54 tissue plasminogen activator (tPA)-treated patients and 15 healthy controls using a real-time
quantitative polymerase chain reaction assay. Neurological outcome was assessed at 48 h. Predictors of neurological
improvement were evaluated by logistic regression analysis, and the additional predictive value of cfDNA over clinical
variables was determined by integrated discrimination improvement (IDI). Stroke patients presented higher baseline
cfDNA than healthy controls (408.5 (179–700.5) vs. 153.5 (66.9–700.5) kilogenome-equivalents/L, p ¼ 0.123). A trend
towards lower cfDNA levels was found in patients who neurologically improved at 48 h (269.5 (143.3–680) vs. 504
(345.9–792.3) kilogenome-equivalents/L, p ¼ 0.130). In logistic regression analysis, recanalization at 1 h and cfDNA <
302.75 kilogenome-equivalents/L was independently associated with neurological improvement after adjustment by age,
gender and baseline National Institutes of Health Stroke Scale score. The addition of cfDNA to the clinical predictive
model improved its discrimination (IDI ¼ 21.2% (9.2–33.3%), p ¼ 0.009). These data suggest that cfDNA could be a
surrogate marker for monitoring tPA efficacy by the prediction of short-term neurological outcome.
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Introduction
Stroke represents the fifth cause of death and one of the
leading causes of disability worldwide.1 Nowadays, intra-
venous thrombolysis with tissue plasminogen activator
(tPA) remains the only approved treatment for acute
stroke.2 Objective tests predicting tPA response in acute
stroke patients, and therefore, short-term neurological out-
come, might be used to guide physicians in the indication
of endovascular therapies in tPA non-responders or to opti-
mize resources improving patient’s allocation.
Circulating cell-free DNA (cfDNA) is found in plasma
under several conditions,3,4 cell death being the major factor
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accounting for cfDNA release.5 Several studies have
assessed the predictive value of cfDNA as a prognostic mar-
ker for long-term outcome in stroke patients6,7 as well as its
role in differentiating between ischaemic and haemorrhagic
stroke.8 However, these studies enrolled few tPA-treated
patients. Therefore, hypothesizing that high cfDNA level
Table 1. Baseline characteristics and univariate predictors of neurological improvement at 48 h.
Neurological improvement
All (N ¼ 54) Yes (N ¼ 33) No (N ¼ 21) p Value
Age (years) 77.0 (70–82) 77.5 (71.5–82) 77 (56.5–83) 0.804
Gender (male) 44.4% 45.5% 42.9% 0.851
Hypertension 68.5% 66.7% 71.4% 0.713
Diabetes 20.4% 24.2% 14.3% 0.497
Dyslipidaemia 35.8% 42.4% 25.0% 0.200
Atrial fibrillation 48.1% 48.5% 47.6% 0.951
Tobacco use 13.2% 15.2% 10.0% 0.697
Coronary disease 25.9% 33.3% 14.3% 0.119
Previous stroke 13.0% 6.1% 23.8% 0.096
Previous disability 3.8% 3.2% 4.8% 0.999
Baseline NIHSS 14.2 + 7.1 13.5 + 5 15.3 + 9 0.429
SBP 154 + 27 156 + 27 152 + 29 0.591
DBP 81 + 14 82.9 + 14 81.5 + 15 0.0.928
Glycaemia 117.5 (97–164) 120 (100–169) 112 (92—129) 0.188
Proximal occlusion 44.4% 45.5% 42.9% 0.851
OCSP TACI 63.0% 72.7% 47.6% 0.041*
PACI 25.9% 24.2% 28.6%
POCI 11.1% 3.0% 23.8%
LACI 0% – –
TOAST Atherothrombotic 18.5% 12.1% 28.6% 0.115
Cardioembolic 57.4% 57.6% 57.1%
Lacunar 0% – –
Undetermined 22.2% 30.3% 9.5%
Uncommon 1.9% 0% 4.8%
Time to tPA (min) 183 + 74 176 + 65 195 + 87 0.383
1-h recanalization 39.2% 54.8% 15.0% 0.004*
NIHSS: National Institutes of Health Stroke Scale; SBP: systolic blood pressure; DBP: diastolic blood pressure; OCSP: Oxfordshire Stroke Project
Classification; TACI: total anterior circulation infarct; PACI: partial anterior circulation infarct; POCI: posterior arterial circulation infarct; LACI: lacunar
infarct; TOAST: Trial of Org 10172 in Acute Stroke Treatment classification; tPA: tissue plasminogen activator.
*p < 0.05.
Figure 1. Differences in baseline cfDNA levels between different groups. Box plots represent median (interquartile range) of cfDNA
levels between the following comparisons: (a) stroke patients (N ¼ 54) versus healthy controls (N ¼ 15). (b) Patients with neurological
improvement at 48 h (N ¼ 33) versus patients without neurological improvement at 48 h (N ¼ 21). cfDNA: circulating cell-free DNA.
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might reflect higher cell death, we aimed to explore the
prognostic value of cfDNA in acute stroke patients treated
with tPA regarding short-term neurological outcome.
Methods
Patients and clinical evaluation
Our target group consisted of acute ischemic stroke patients
admitted to the stroke unit of our centre within the first 4.5
h after symptoms onset. Fifty-four patients with non-
lacunar stroke involving the middle cerebral artery or the
basilar artery territories and 15 age- and gender-matched
healthy controls were evaluated. All patients received
recombinant tPA in a standard dose, and recanalization was
assessed at the end of tPA infusion by transcranial Doppler
with the thrombolysis in brain ischaemia score.9 All
patients underwent a complete workup on neurological
assessment and ancillary tests as previously published.10
Neurological outcome was assessed at 48 h, and neurolo-
gical improvement was defined as a decrease of four or
more points in the National Institutes of Health Stroke
Scale (NIHSS).11 Written informed consent was obtained
from all patients or relatives, and the study protocol was
approved by the local Ethics Committee.
Blood sampling and cfDNA measurement
Blood samples were taken on admission, before tPA
administration (<4.5 h), centrifuged (8 min–2000  g) and
DNA from 400 mL of serum was extracted using MagNA
Pure and Nucleic Acid Isolation Kit I (Roche Diagnostics,
Basel, Switzerland). cfDNA was measured using quantita-
tive polymerase chain reaction (PCR) analysis (LightCy-
cler 480 Real-Time PCR; Roche Diagnostics) using LC480
Probes Master Kit (Roche Diagnostics). b-Globin hydro-
lysis probes system comprises primers beta-globin-354F
and beta-globin-455 R and a dual-labelled fluorescent
probe betaglobin-402 T. PCR conditions were 95C for 5
min and 61C for 15 min for 48 cycles. The final size of the
amplicon was 102 bp. The experiment was repeated twice
to evaluate the reproducibility of the results.
Statistical analysis
SPSS v15.0 [Chicago, SPSS Inc.] software was used for statis-
tical analysis.NormalitywasassessedbyKolmogorov–Smirnov
Table 2. Factors associated with cfDNA levels.
Yes No P Value
Gender (male) 383 (173–1435) 346 (159–628) 0.121
Hypertension 383 (158–665) 405 (173–999) 0.999
Diabetes 185 (127–688) 383 (179–913) 0.512
Dyslipidaemia 383 (167–913) 346 (164–657) 0.978
Atrial fibrillation 384 (172–672) 309 (151–801) 0.972
Tobacco use 597 (237–1447) 346 (158–673) 0.373
Coronary disease 321 (147–808) 383 (172–650) 0.961
Previous stroke 639 (102–2045) 383 (166–657) 0.632
Previous disability 617 (135–1099) 383.5 (167–688) 0.943
Proximal occlusion 408 (206–665) 309 (115–801) 0.470









48-h improvement 227 (135–688) 457 (309–927) 0.123
Correlation coefficient p Value
Age R ¼ 0.075 0.589
Baseline NIHSS R ¼ 0.096 0.492
SBP R ¼ 0.072 0.612
DBP R ¼ 0.095 0.503
Glycaemia R ¼ 0.167 0.242
Time to tPA R ¼ 0.065 0.646
NIHSS: National Institutes of Health Stroke Scale; SBP: systolic blood pressure; DBP: diastolic blood pressure; OCSP: Oxfordshire Stroke Project
Classification; TACI: total anterior circulation infarct; PACI: partial anterior circulation infarct; POCI: posterior arterial circulation infarct; LACI: lacunar
infarct; TOAST: Trial of Org 10172 in Acute Stroke Treatment classification; tPA: tissue plasminogen activator.
*p < 0.05.
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test. Normally distributed variables were analysed by
Student t test, and non-normally distributed variables
were analysed by Mann–Whitney U or Kruskal–Wallis
tests. In the univariate analysis, intergroup differences
were assessed by Pearson w2 test for categorical vari-
ables. Cut-off points were obtained from receiver oper-
ating characteristic curves. To build predictive models,
all clinical variables associated with neurological
improvement at p value <0.15 in univariate analysis
(Oxfordshire Stroke Project Classification, Trial of Org
10172 in Acute Stroke Treatment classification, 1-h
recanalization, coronary artery disease and previous
stroke) were included in a forward stepwise logistic
regression analysis. Afterwards, cfDNA was added by
Enter method to build a second predictive model. For
both models, odds ratios (ORs) were adjusted by age,
gender and baseline NIHSS score. Comparisons between
models were made with integrated discrimination
improvement (IDI) index.12
Results
Demographic data are summarized in Table 1. cfDNA
levels trended to be higher in stroke patients compared
to controls (408.5 (179–700.5) vs. 153.5 (66.9–700.5)
kilogenome-equivalents/L, p ¼ 0.123; Figure 1(a)). There
were no significant associations between cfDNA levels
and baseline characteristics of stroke patients (Table 2),
neither baseline stroke severity or aetiology, although
patients with previous stroke and those with previous dis-
ability had non-significant higher cfDNA levels. Regard-
ing neurological outcome, 33 patients (61.1%) improved
at 48 h. No patient developed tPA-related complications
such as symptomatic haemorrhagic transformation or
malignant oedema. Patients who improved at 48 h trended
to have lower cfDNA levels (286.5 (152–688) vs. 526
(382.8–927.5) kilogenome-equivalents/L, p ¼ 0.123;
Figure 1(b)).
A cut-off point of cfDNA <302.75 kilogenome-
equivalents/L was found to have 81% sensitivity and
55% specificity for the prediction of 48 h neurological
improvement. Patients with cfDNA levels below this
cut-off point were significantly more prone to improve
at 48 h than those with higher levels (81.8% vs. 46.7%,
p ¼ 0.010). In logistic regression analysis, after adjust-
ing by age, gender and baseline NIHSS score, the pres-
ence of arterial recanalization 1 h after tPA (adjusted
OR (adjOR) ¼ 43.8(3.1–620.9), p ¼ 0.005) and cfDNA
levels <302.75 kilogenome-equivalents/L (adjOR ¼
27.1(2.63–279.2), p ¼ 0.006) were the only independent
predictors of 48 h improvement in our cohort. When
models including or not the biomarker were compared,
assessing cfDNA levels resulted in improved discrimi-
nation (IDI ¼ 21.2% (9.2–33.3%), p ¼ 0.0005; Figure 2,
Table 3).
Discussion
Our study showed that baseline cfDNA was an independent
predictor of neurological improvement at 48 h in stroke
patients treated with tPA. Moreover, cfDNA <302.75 kilo-
genome-equivalents/L improved the prediction of neurolo-
gical improvement regarding clinical variables and after
adjustment by age, gender and baseline NIHSS score.
Although higher cfDNA levels have been previously asso-
ciated with long-term disability and mortality after
stroke,6,7 a diagnostic test, which is able to identify early
those patients with a higher chance of short-term neurolo-
gical improvement, could be easily used by clinicians, to
indicate early the rescue procedures (activation of interven-
tional teams, inclusion in clinical trials) for patients with a
low chance to improve after intravenous tPA treatment or,
conversely, patients with a high chance to improve could be
safely discharged from scarce resources such as stroke
unit’s beds.
High levels of cfDNA in acute stroke patients have been
associated also with infarct volume or baseline neurologi-
cal impairment, which seems logical while cfDNA is an
indicator of cell death.13,14 In accordance with these data,
we found that patients with previous stroke and those with
previous disability had higher cfDNA levels, which may
indicate a sustained inflammatory response or a greater
Figure 2. Comparison between predictive models for 48 h
neurological improvement. Light bars represent the predictive
ability of the clinical model, composed by 1-h recanalization
adjusted by age, gender and baseline National Institutes of Health
Stroke Scale score. Dark bars represent the predictive ability of
the second model, constructed by adding cfDNA levels <302.75
kilogenome-equivalents/L over the only clinical model. The inte-
grated discrimination improvement index was 21.2% (9.2–33.3%),
p ¼ 0.0005. cfDNA: circulating cell-free DNA.
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level of cell death in these patients, although these results
did not reach statistical significance. The main finding of
our study, however, was an association with short-term
outcome. Since this association has been noted in tPA-
treated patients, it might not indicate just a higher infarct
size or neurological deficit, but a greater BBB damage as
has been described,8 and therefore a higher chance of com-
plications related to this breakdown in tPA-treated patients
such as haemorrhagic transformation or oedema. However,
high cfDNA levels have also been associated with other
conditions related to cell death.3,4 Although in our study
cfDNA levels were not related to baseline comorbidities or
vascular risk factors, we cannot exclude that these differ-
ences were related to some conditions not assessed in the
present study.
Our study has some limitations. First, our sample size
was relatively small and this fact could be responsible
for missing some associations, such as a less number of
patients developing neurological worsening or none with
tPA-related complications. Second, our data from short-
term neurological outcome has been derived from a
cohort of tPA-treated patients and extrapolation of the
results to all stroke patients should be carefully inter-
preted. Third, final infarct volume was not measured,
and so this parameter could not be used for further
adjustments, although some other parameter reflecting
similar information such as baseline NIHSS score was
used to adjust the model.
Besides these limitations, cfDNA could represent a
surrogate marker for monitoring tPA efficacy with the
prediction of short-term neurological outcome, improving
the prediction that may be done with clinical information.
However, our results are still of preliminary nature, and
future studies are needed to replicate these results, as well
as the possible underlying association with symptomatic
haemorrhagic transformation.
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